Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol/palmitoylethanolamide - SciSparc

Next Previous
Drug Profile

Cannabidiol/palmitoylethanolamide - SciSparc

Alternative Names: cannabidiol/CannAmide™; CBD/PEA - SciSparc; RESPECTRUM; SCI–210; THX 210

Latest Information Update: 11 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therapix Biosciences
  • Developer SciSparc
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cyclohexenes; Drug withdrawal therapies; Ethanolamines; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Palmitic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Pervasive child development disorders
  • Preclinical Status epilepticus
  • No development reported Inflammation

Most Recent Events

  • 04 Feb 2025 Cannabidiol/palmitoylethanolamide is still in clinical trials for Pervasive child development disorders (In children) in Israel
  • 04 Feb 2025 Cannabidiol/palmitoylethanolamide is still in preclinical trials for Status epilepticus in Israel
  • 28 Jan 2025 No recent reports of development identified for clinical-Phase-Unknown development in Pervasive-child-development-disorders(In children) in Israel (PO, Pill)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top